The role of biosimilars in the treatment of rheumatic diseases

@article{Drner2013TheRO,
  title={The role of biosimilars in the treatment of rheumatic diseases},
  author={Thomas D{\"o}rner and Vibeke Strand and Gilberto Casta{\~n}eda-Hern{\'a}ndez and Gianfranco Ferraccioli and John Dudley Isaacs and Tore K. Kvien and Emilio Martı́n-Mola and Thomas Mittendorf and Josef S. Smolen and Gerd R{\"u}diger Burmester},
  journal={Annals of the Rheumatic Diseases},
  year={2013},
  volume={72},
  pages={322 - 328}
}
The first biological therapeutics in rheumatology are approaching patent expiration, encouraging development of ‘follow-on’ versions, known as ‘biosimilars’. Biological agents range from simple replacement hormones to complex monoclonal antibodies and soluble receptors: large, intricate proteins with unique tertiary and quaternary structures that are inherently difficult to replicate. Post-translational modifications, such as glycosylation, may occur from changes in cell lines and/or… 
Biosimilars: lights and shadows in rheumatology
TLDR
Before their approval and marketing, specific guidelines and steps imposed by national and/or international regulatory agencies should be followed along with the respect of scientific societies position in each specific contest.
Biosimilars to treat inflammatory arthritis: the challenge of proving identity
TLDR
The results of the first randomised, prospective clinical trials comparing a biosimilar to an original (or ‘innovator’) biopharmaceutical for a rheumatic disease indication, are published.
Current and future biosimilars: potential practical applications in rheumatology
TLDR
Biosimilars will soon be in the market, and their use in rheumatic diseases will likely change the authors' treatment approach, and rheumatologists and other health-care professionals will have to be familiarized with the concept and the points of debate.
Similar and mimics: Latin America biosimilar regulations
TLDR
This paper summarizes the status of biosimilarars in Latin America, focusing on the regulations, extrapolation of indication and the products available in the countries of the region with the aim to provide key information about the use of biosimilars in the treatment of rheumatic diseases.
The Future Potential of Biosimilars Targeting B-Cells
The patent and regulatory data protection periods for the first and second waves of biological agents based on recombinant proteins have started to expire, leaving open the potential for development
Biosimilar DMARDs: What Does the Future Hold?
TLDR
In this article, biosimilar disease-modifying anti-rheumatic drugs (DMARDs) are put into perspective: what they are, the stepwise manufacturing process and the available mechanisms that regulate the thorough comparability exercise are reviewed.
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
TLDR
The differences between biosimilars and intended copies are explored and key concepts related to biosimilARS are described, which may facilitate decision making about the appropriate use of biosimilar for patients with rheumatic and musculoskeletal diseases.
Protein biosimilars: Opportunities and challenges
Introduction Therapeutic proteins are next-generation drugs in the prevention and treatment of diseases, in particular human critical illness. The expiration of patents in the originally approved
Biosimilars in rheumatology: current perspectives and lessons learnt
TLDR
The main challenges posed by biosimilars are addressed, such as the extrapolation of indications to diseases only studied for the reference drug, and the definition of strategies for adequate pharmacovigilance to monitor biosimilar after marketing approval.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 103 REFERENCES
The advent of biosimilar therapies in rheumatology—“O Brave New World”
TLDR
The development of biosimilar therapies for the treatment of patients with rheumatic diseases could potentially result in substantial cost savings for patients and health care providers, and consequently, increased availability of effective therapies.
Biosimilars: opportunity or cause for concern?
  • S. Roger, A. Mikhail
  • Medicine
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2007
TLDR
The issues surrounding biosimilars, including manufacturing, quality control, clinical efficacy and side effects, and how government and industry regulations are evolving to deal with these topics are focused on.
The State of the Art in the Development of Biosimilars
TLDR
The development and commercialization of biosimilars can help address unmet medical needs by improving access to well‐established therapeutic interventions while improving health‐care affordability.
Biosimilar therapeutics—what do we need to consider?
TLDR
Biosimilars present a new set of challenges for regulatory authorities when compared with conventional generics, and documents recently published by the European Medicines Agency outlining requirements for the market approval of biosimilars provide much-needed guidance.
The challenge of biosimilars.
TLDR
Biosimilars should provide cost savings and greater accessibility to biopharmaceuticals and a thorough knowledge surrounding biosimilars will ensure the appropriate use of biophARMaceuticals.
Immunogenicity of biopharmaceuticals.
  • M. Kessler, D. Goldsmith, H. Schellekens
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2006
The availability of biopharmaceuticals has been increasing over the past decade and as their patents expire, the emergence of biosimilar agents approaches. The primary issue of concern for the safety
The emergence of biosimilar insulin preparations--a cause for concern?
TLDR
Every biosimilar insulin and insulin analog should be assessed by well-defined globally harmonized preclinical and clinical studies followed by post-marketing pharmacovigilance programs, in the interest of people with diabetes worldwide.
Bioequivalence and the immunogenicity of biopharmaceuticals
The expiry of the first patents for recombinant-DNA-derived biopharmaceuticals will open the possibility of marketing generics, if they can be shown to be essentially similar to the innovator
Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act
Introduction For small molecule drug products, when an innovative (brandname) drug product is going off patent, pharmaceutical and/ or generics companies may seek regulatory approval of the generic
Pure red-cell aplasia due to anti-erythropoietin antibodies.
  • K. Eckardt, N. Casadevall
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2003
TLDR
A significant increase in the frequency of Epoetin-induced antibodies remained a very rare complication for many years, however, recently, a significant increase of this complication, which leads to severe inhibition of red cell production, was noted.
...
1
2
3
4
5
...